Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients PHILADELPHIA, Pa. and OXFORDSHIRE, UK.

Promising Data from Phase 1 Trial with

ADP-A2AFP in Liver Cancer at the International Liver Congress

Confirm Safety Profile and Demonstrate Potential Benefit for Patients

PHILADELPHIA, Pa. and OXFORDSHIRE, UK., August 28, 2020

- Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented

data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International Liver Congress (ILC). One patient

out of four dosed with 5 billion or more cells had a complete response, which was reported previously. The data also demonstrate

an acceptable safety profile in patients with hepatocellular carcinoma (HCC).

"A complete response in a patient with advanced liver

cancer, and the anti-tumor activity we have reported in other patients with an acceptable safety profile, to date, further support

the continued investigation of ADP-A2AFP," said Elliot Norry, Adaptimmune's Chief Medical Officer. "We remain

encouraged by the potential of this therapy and we are fully committed to developing ADP-A2AFP for people with HCC. We have reported

results for four patients at doses of 5 billion cells or more and we are looking forward to sharing more data as we continue to

treat patients in the expansion phase of the trial. Further, we continue to review our translational findings and are evaluating

ways to improve the therapy, if necessary."

Dr. Bruno Sangro of Clinica Universidad de Navarra presented

data from Cohort 3 and the expansion phase of the ADP-A2AFP Phase 1 trial during an oral presentation at ILC. Tim Meyer of University

College London presented additional data from Cohorts 1 and 2 during a poster presentation. A video is available on Adaptimmune's

website (https://youtu.be/qAHamb3Yi8Y) of Elliot Norry, and Mark Dudley, SVP of Early Stage Development, discussing these

data. The oral presentation and poster presentation are available online through the congress web site.

Topline data from ILC 1

data summarized are for patients with HCC with a data cut-off of July 6, 2020. Data from non-HCC patients to be presented at a

Overview of Trial Design

Adaptimmune is a clinical-stage biopharmaceutical company focused

on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific

Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple

Forward-Looking Statements

This release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain

risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated

by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities

and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization

processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from

those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our

Quarterly Report on Form 10-Q filed with the SEC on August 6, 2020, and our other SEC filings. The forward-looking statements

contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update

such forward-looking statements to reflect subsequent events or circumstances.

S bastien Desprez - VP, Communications and Investor

Juli P. Miller, Ph.D. - Senior Director, Investor